Demographic, risk, and spatial factors associated with over-the-counter syringe purchase among injection drug users

American Journal of Epidemiology

Volumn 176, Issue 1, 2012, Pages 14-23

  Stopka, Thomas J ^a   Lutnick, Alexandra ^b   Wenger, Lynn D ^b   DeRiemer, Kathryn ^a   Geraghty, Estella M ^a   Kral, Alex H ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Geographic information system; HIV; Pharmacies; Substance abuse, intravenous; Syringes

Indexed keywords

CONSUMPTION BEHAVIOR; DEMOGRAPHY; DISEASE CONTROL; DRUG USER; GIS; HEALTH RISK; HEALTH SERVICES; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; MEDICINE; MULTIVARIATE ANALYSIS; RISK FACTOR; SAMPLING;

ADULT; AFRICAN AMERICAN; ARTICLE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG USE; FEMALE; GEOGRAPHIC INFORMATION SYSTEM; HUMAN; INJECTION; MALE; RISK FACTOR; SPATIAL DISCRIMINATION; SYRINGE;

ADULT; COMMERCE; CROSS-SECTIONAL STUDIES; DANGEROUS BEHAVIOR; DISEASE TRANSMISSION, INFECTIOUS; DRUG USERS; FEMALE; GEOGRAPHIC INFORMATION SYSTEMS; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACIES; REGRESSION ANALYSIS; RESIDENCE CHARACTERISTICS; RISK; SAN FRANCISCO; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES;

CALIFORNIA; SAN FRANCISCO [CALIFORNIA]; UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84863326599     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr492     Document Type: Article

References (46)

1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. HIV Incidence Surveillance Group. JAMA. 2008;300(5):520-529.
2. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999;107(6B):2S-9S.
3. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46(12):1852-1858.
4. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714. (Pubitemid 46780630)
5. Garfein RS, Doherty MC, Monterroso ER, et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S11-S19. (Pubitemid 28304463)
6. Chen JL, Fullerton KE, Flynn NM. Necrotizing fasciitis associated with injection drug use. Clin Infect Dis. 2001;33(1):6-15. (Pubitemid 32554496)
7. Sandrock CE, Murin S. Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism. Chest. 2001;120(2):562-566. (Pubitemid 32881276)
8. Passaro DJ, Werner SB, McGee J, et al. Wound botulism associated with black tar heroin among injecting drug users. JAMA. 1998;279(11):859-863. (Pubitemid 28185551)
9. Binswanger IA, Kral AH, Bluthenthal RN, et al. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000;30(3):579-581. (Pubitemid 30205308)
10. Kimura AC, Higa JI, Levin RM, et al. Outbreak of necrotizing fasciitis due to Clostridium sordellii among black-tar heroin users. Clin Infect Dis. 2004;38(9):e87-e91.
11. Bluthenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000;14(5):605-611. (Pubitemid 30209702)
12. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997;349(9068):1797-1800. (Pubitemid 27257556)
13. MacDonald M, Law M, Kaldor J, et al. Effectiveness of needle and syringe programs for preventing HIV transmission. Int J Drug Policy. 2003;14(5/6):353-357. (Pubitemid 37412229)
14. Fuller CM, Galea S, Caceres W, et al. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007;97(1):117-124. (Pubitemid 46067693)
15. Deibert RJ, Goldbaum G, Parker TR, et al. Increased access to unrestricted pharmacy sales of syringes in Seattle-King County, Washington: structural and individual-level changes, 1996 versus 2003. Am J Public Health. 2006;96(8):1347-1353. (Pubitemid 44198653)
16. Burris S, Welsh J, Ng M, et al. State syringe and drug possession laws potentially influencing safe syringe disposal by injection drug users. J Am Pharm Assoc (Wash). 2002;42(6 suppl 2):S94-S98.
17. Singer M, Baer HA, Scott G, et al. Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut. Public Health Rep. 1998;113(suppl 1):81-89. (Pubitemid 29330149)
18. Compton WM, Horton JC, Cottler LB, et al. A multistate trial of pharmacy syringe purchase. J Urban Health. 2004;81(4):661-670. (Pubitemid 39457948)
19. Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc (Wash). 2002;42(6 suppl 2):S77-S82.
20. Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr. 2005;39(4):471-477. (Pubitemid 41003795)
21. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6-7):777-813. (Pubitemid 43995128)
22. Neaigus A, Zhao M, Gyarmathy VA, et al. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health. 2008;85(3):309-322.
23. Friedman SR, Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001;91(5):791-793. (Pubitemid 32397917)
24. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86(5):642-654. (Pubitemid 26145476)
25. Jones TS, Coffin PO. Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal. J Am Pharm Assoc (Wash). 2002;42(6 suppl 2):S6-S9.
26. Syringe exchange programs - United States, 2008. MMWR Morb Mortal Wkly Rep. 2010;59(45):1488-1491.
27. Reich W, Compton WM, Horton JC, et al. Injection drug users report good access to pharmacy sale of syringes. J Am Pharm Assoc (Wash). 2002;42(6 suppl 2):S68-S72.
28. Junge B, Vlahov D, Riley E, et al. Pharmacy access to sterile syringes for injection drug users: attitudes of participants in a syringe exchange program. J Am Pharm Assoc (Wash). 1999;39(1):17-22.
29. Stopka TJ, Garfein RS, Ross A, et al. Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health. 2007;84(1):116-125. (Pubitemid 46147375)
30. Garfein RS, Stopka TJ, Pavlinac PB, et al. Three years after legalization of nonprescription pharmacy syringe sales in California: where are we now? J Urban Health. 2010;87(4):576-585.
31. Riley ED, Kral AH, Stopka TJ, et al. Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. J Urban Health. 2010;87(4):534-542.
32. Buchanan D, Shaw S, Teng W, et al. Neighborhood differences in patterns of syringe access, use, and discard among injection drug users: implications for HIV outreach and prevention education. J Urban Health. 2003;80(3):438-454. (Pubitemid 37486647)
33. Sullivan AB, Gesink DC, Brown P, et al. Are neighborhood sociocultural factors influencing the spatial pattern of gonorrhea in North Carolina? Ann Epidemiol. 2011;21(4):245-252.
34. Cooper HL, Bossak B, Tempalski B, et al. Geographic approaches to quantifying the risk environment: drug-related law enforcement and access to syringe exchange programmes. Int J Drug Policy. 2009;20(3):217-226.
35. Bluthenthal RN, Watters JK. Multimethod research from targeted sampling to HIV risk environments. NIDA Res Monogr. 1995;157:212-230.
36. Watters J, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Prob. 1989;36(4):416-430.
37. Wenger LD, Martinez AN, Carpenter L, et al. Syringe disposal among injection drug users in San Francisco. Am J Public Health. 2011;101(3):484-486.
38. Kral AH, Malekinejad M, Vaudrey J, et al. Comparing respondent-driven sampling and targeted sampling methods of recruiting injection drug users in San Francisco. J Urban Health. 2010;87(5):839-850.
39. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199-200. (Pubitemid 41373523)
40. Fuller CM, Galea S, Blaney S, et al. Explaining the relationship between race/ethnicity and pharmacy purchased syringes among injection drug users in New York City. Ethn Dis. 2004;14(4):589-596. (Pubitemid 39445582)
41. Costenbader EC, Zule WA, Coomes CC. Racial differences in acquisition of syringes from pharmacies under conditions of legal but restricted sales. Int J Drug Policy. 2010;21(5):425-428.
42. Rose VJ, Raymond HF. Evaluation of nonprescription syringe sales in San Francisco. J Am Pharm Assoc. 2010;50(5):595-599.
43. Pollini RA, Lozada R, Gallardo M, et al. Barriers to pharmacy-based syringe purchase among injection drug users in Tijuana, Mexico: a mixed methods study. AIDS Behav. 2010;14(3):679-687.
44. Miller CL, Strathdee SA, Li K, et al. A longitudinal investigation into excess risk for blood-borne infection among young injection drug users (IUDs). Am J Drug Alcohol Abuse. 2007;33(4):527-536. (Pubitemid 47196705)
45. Hahn JA, Page-Shafer K, Lum PJ, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186(11):1558-1564. (Pubitemid 35379631)
46. Dowling-Guyer S, Johnson M, Fisher D, et al. Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment. 1994;1:383-392.